Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpopulations with Vp4 portal vein tumor thrombosis (P...

Full description

Bibliographic Details
Main Authors: Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, Valeriy Breder
Format: Article
Language:English
Published: Karger Publishers 2024-06-01
Series:Liver Cancer
Online Access:https://beta.karger.com/Article/FullText/539897

Internet

https://beta.karger.com/Article/FullText/539897

Similar Items